New Nasal Vaccines, Korro Stock Dips, J&J and Merck Acquisitions, and Dyno GATC
About this episode
The episode discusses the latest advancements in nasal vaccines and significant business developments in the biotech industry.
Nasal vaccines show new promise for human papillomavirus (HPV) to address cervical cancer and whooping cough. In business news, Korro's stock craters 81% as AATD interim Phase I/II results miss expectations. Additionally, Johnson & Johnson acquires Halda to expand their cancer pipeline while Merck acquires Cidara to boost antivirals. Lastly, the inaugural Genetic Agency Technology Conference (GATC) hosted by Dyno Therapeutics brought together a diverse group of researchers, entrepreneurs, and patient advocates to discuss the mission of genetic agency, or an individual’s ability to take action at the genetic level to live a healthier life. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base : Cervical Cancer May Be Treatable with Intranasal Nanogel Vaccine GEN , November 15, 2025 Novel Nasal Spray Vaccine for Pertussis Shows Promise By Corinna Singleman, PhD, GEN , November 12, 2025 StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on…
More episodes of Touching Base
- AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains
- Drugs from a Text Prompt, Wegovy Pill Competition Dampens Lilly’s Surge
- Agentic AI, Virtual Cell, LNP Vaccine Boosters, Engineered Organs, and Mergers
- Bacteria 4D Simulation, Safer Large Gene Insertion, uniQure Roller Coaster
- AI for Scientists, FDA Reverses Course, and Advances in Cancer Therapeutics
- Women in Science, Robotics, Automation, SLAS, and Lilly Updates
Explore listener stats, chart rankings, contacts and more on the Touching Base podcast page.